In CKD, Fish Oil Doesn’t Up Hemodialysis Graft PatencyLast Updated: May 01, 2012. For patients with stage 5 chronic kidney disease, fish oil does not improve synthetic hemodialysis graft patency, according to a study published in the May 2 issue of the Journal of the American Medical Association.
TUESDAY, May 1 (HealthDay News) -- For patients with stage 5 chronic kidney disease, fish oil does not improve synthetic hemodialysis graft patency, according to a study published in the May 2 issue of the Journal of the American Medical Association.
Charmaine E. Lok, M.D., from the University of Toronto and Toronto General Hospital, and colleagues investigated the effect of fish oil on synthetic hemodialysis graft patency in 201 adults with stage 5 chronic kidney disease. Participants from the Fish Oil Inhibition of Stenosis in Hemodialysis Grafts study were randomized to receive fish oil capsules (four 1-g capsules/day) or matching placebo on day seven after graft creation, and were followed for 12 months. The primary outcome was the proportion of patients experiencing graft thrombolysis or radiological or surgical intervention during follow-up.
The researchers found that graft patency did not differ between the fish oil and placebo groups (48 and 62 percent, respectively; relative risk, 0.78). In the fish oil group, the rate of graft failure was significantly lower (3.43 versus 5.95 per 1,000 access-days; incidence rate ratio [IRR], 0.58). In addition, there were significantly fewer thromboses (1.71 versus 3.41 per 1,000 access-days; IRR, 0.50), fewer corrective interventions (2.89 versus 4.92 per 1,000 access-days; IRR, 0.59), improved cardiovascular event-free survival (hazard ratio, 0.43), and lower mean systolic blood pressure (−3.61 versus 4.49 mm Hg) in the fish oil group.
"Among patients with new hemodialysis grafts, daily fish oil ingestion did not decrease the proportion of grafts with loss of native patency within 12 months," the authors write.
Several of the authors disclosed financial ties to the medical technology and pharmaceutical industries.
|Previous: Methodological Heterogeneity Seen in Clinical Trials||Next: Elelyso Approved for Type 1 Gaucher Disease|
Reader comments on this article are listed below. Review our comments policy.